In the BioHarmony Drug Report Database

"Preview" Icon

Pralsetinib

Gavreto (pralsetinib) is a small molecule pharmaceutical. Pralsetinib was first approved as Gavreto on 2020-09-04. It is used to treat non-small-cell lung carcinoma in the USA. The pharmaceutical is active against proto-oncogene tyrosine-protein kinase receptor Ret. In addition, it is known to target vascular endothelial growth factor receptor 2. Gavreto’s patent is valid until 2036-11-01 (FDA).

 

Trade Name

 

Gavreto
 

Common Name

 

pralsetinib
 

ChEMBL ID

 

CHEMBL4582651
 

Indication

 

non-small-cell lung carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Pralsetinib structure rendering